US medtech company PharmaJet has appointed Nanette Cocero, Ph.D. to its Board of Directors.
Dr Cocero has broad commercial and business experience within the pharmaceutical industry, coupled with an extensive clinical and scientific background.
PharmaJet CEO and President, Chris Cappello, said:
“The addition of Dr. Cocero continues to build on the pharmaceutical expertise within PharmaJet.
“Her extensive vaccine background and demonstrated leadership will be an asset to our company, and I look forward to her contributions as we drive global expansion and adoption of our innovative solutions,”
Dr Cocero was most recently the Global President of Pfizer Vaccines, where she led a >$30 billion (£23.1 billion) portfolio and drove the development, marketing and delivery of innovative vaccines.
Dr Cocero led the global commercialisation and distribution of more than two billion doses of the Pfizer-BioNTech COVID-19 vaccine to 152 countries.
She also held senior positions across Pfizer’s core therapeutic areas including oncology, inflammation, immunology internal medicine, and rare diseases.
Dr Cocero said:
“I am looking forward to joining PharmaJet’s distinguished BOD and leadership in their exciting journey ahead as we look to have a profound impact on global public health.”
PharmaJet aims to enable greater access to life-saving vaccines and pharmaceuticals globally.
